T›kay›c› Periferik Arter Hastal›¤›nda ‹laç Sal›n›ml› Balon ve Stentler

Periferik arter hastal›¤› sistemik aterosklerozun klinik tablolar›ndan biridir. Son on y›lda, özellikle stent alan›ndaki teknolojik geliflmeler, periferik arter hastal›¤› tedavisi için aç›k cerrahi prosedürler yerine, morbidite oran› düflük perkütan endovasküler tedavinin tercih edilmesine neden olmufltur. Bununla birlikte restenoz, yeni dizayn edilmifl ç›plak nitinol stentlerde bile majör engel oluflturmaya devam etmektedir. Son y›llarda ilaç kapl› stentler periferik arter hastal›klar›n›n tedavisinde kullan›lmaya bafllanm›flt›r. Bu yaz›da, yak›n zamanda, alt ekstremite periferik arter hastal›¤›n›n tedavisinde ilaç kapl› stentlerle yap›lm›fl çal›flmalar› ve sonuçlar›n› inceledik.

Balloon Angioplasty and Drug Eluting Stenting for Treatment of Peripheral Arterial Occlusive Disease

Peripheral arterial disease is one of the manifestations of systemic atherosclerosis. In the last decade, remarkable technological advances, especially in the stent area, have shifted revascularization strategies from traditional open surgical approaches toward less morbide percutaneous endovascular treatments. However, even with new designed nitinol bare stents, restenosis remains as the major obstacle of this procedures. More recently, drug eluting stent platforms have been used to treat atherosclerotic peripheral arterial disease. In this article, we reviewed new studies relevant to drug eluting stents for lower extremity peripheral arterial occlusive disease.

___

  • Duda SH, Pusich B, Richter G, et al. Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease: six-month results. Circulation 2002;106:1505-9.
  • Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol. 2005; 16:331-8.
  • Bosiers M, Peeters P, D’Archambeau O, et al. AMS INSIGHT-absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Interv Radiol. 2009;32(3):424-35.
  • Rand T, Basile A, Cejna M, et al. PTA versus carbofilm-coated stents in infrapopliteal arteries: pilot study. Cardovasc Interv Radiol. 2006;29(1):29-38.
  • Siablis et al. Sirolimus eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia. Enduring 1-year clinical and angiographic benefit. J Endovasc Ther. 2007;14:241-50.
  • Bosiers M, Deloose K, Verbist J et al. Percutaneous transluminal angioplasty for treatment of “below-the-knee” critical limb ischemia: early outcomes following the use of sirrolimuseluting stents. J Cardiovasc Surg (Torino) 2006; 47(2):171-6.
  • Scheinert D, Ulrich M, Scheinert S, et al. Comparison of sirolimus-eluting vs. bare-metal stents for the treatment of infrapopliteal obstructions. EuroInterv. 2006;2:169-74.
  • Commeau P, Barragan P, Roquebert PO. Sirolimus for below the knee lesions: mid-term results of SiroBTK study. Catheter Cardiovasc Interv. 2006;68:793-8.
  • Siablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of Paklitaxel-eluting stents for critical limb ischemia: Midterm angiographic and clinical results. J Vasc Interv Radiol . 2007; 18:1351-61.
  • Deloose K, Bosiers M, Peeters P. One year outcome after primary stenting of infrapopliteal lesions with the Chromis Deep stent in the management of critical limb ischemia. EuroInterv. 2009;5:310-17.
  • Bosiers M, Deloose K, Verbist J, et al. Nitinol stenting for treatment of “below-the-knee” critical limb ischemia: 1-year angiographic outcome after Xpert stent implantation. XpertBTK study. J Cardiovasc Surg. 2007;48(4):455-61.
  • Drug Eluting Stents In the Critically Ischemic Lower Leg (DESTINY) trial . ClinicalTrials.gov identifier NCT00510393.